1. REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design

2. REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Efficacy Outcomes

3. REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Most Frequent TEAEs

4. REFLECT: First-Line Lenvatinib vs Sorafenib in HCC QoL Measures

5. CheckMate 040: Nivolumab in HCC Study Design

6. CheckMate 040: OS With Nivolumab in Sorafenib-Naive Patients With Advanced HCC

7. CheckMate 040: Duration of Response With Nivolumab in Sorafenib-Naive Patients With HCC

8. CheckMate 459: Nivolumab vs Sorafenib as First-Line Treatment in Advanced HCC

9. Abbreviations

10. Abbreviations (cont)

11. Abbreviations (cont)